Recommendations for human epidermal growth factor receptor 2 testing in breast

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3997-4013

  Wolff, Antonio C ^a   Hammond, M Elizabeth H ^c   Hicks, David G ^d   Dowsett, Mitch ^e   McShane, Lisa M ^b   Allison, Kimberly H ^f   Allred, Donald C ⁱ   Bartlett, John M S ^j   Bilous, Michael ^l   Fitzgibbons, Patrick ^g   Hanna, Wedad ^k   Jenkins, Robert B ^m   Mangu, Pamela B ⁿ   Paik, Soonmyung ^o   Perez, Edith A ^p   Press, Michael F ^h   Spears, Patricia A ^q   Vance, Gail H ^r   Viale, Giuseppe ^s   Hayes, Daniel F ^t  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g ST JUDE MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^l UNIVERSITY OF WESTERN SYDNEY   (Australia)

^m MAYO CLINIC   (United States)

ⁿ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^o NSABP Foundation Inc   (United States)

^p MAYO CLINIC   (United States)

^q NORTH CAROLINA STATE UNIVERSITY   (United States)

^r INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY OF MILAN   (Italy)

^t UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COPY NUMBER VARIATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; FEMALE; GENETICS; ONCOLOGY; STANDARDS; UNITED STATES; STANDARD;

BREAST NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84890254448     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.9984     Document Type: Article

References (155)

1. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007 (Pubitemid 46174133)
3. Hammond EH, Wolff AC, Hayes DF, et al: Reply to G. Sauter et al. J Clin Oncol 27:e153-e154, 2009; author reply e155-e157
4. Hammond ME, Hayes DF, Wolff AC: Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 29:e458, 2011
5. Wolff AC, Hammond ME, Hayes DF: Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:957-958, 2012
6. Dowsett M, Procter M, McCaskill-Stevens W, et al: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27:2962-2969, 2009
7. Perez EA, Reinholz MM, Hillman DW, et al: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307-4315, 2010
8. Vance GH, Barry TS, Bloom KJ, et al: Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med 133:611-612, 2009
9. Gunn S, Yeh IT, Lytvak I, et al: Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 10:396, 2010
10. Yeh IT, Martin MA, Robetorye RS, et al: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22:1169-1175, 2009
11. Bartlett JM, Campbell FM, Mallon EA: Determination of HER2 amplification by in situ hybridization: When should chromosome 17 also be determined? Am J Clin Pathol 130:920-926, 2008
12. Shah SS, Wang Y, Tull J, et al: Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol 18:30-33, 2009
13. Bartlett AI, Starcyznski J, Robson T, et al: Heterogeneous HER2 gene amplification: Impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 136:266-274, 2011
14. Marchiò C, Lambros MB, Gugliotta P, et al: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219:16-24, 2009
15. Troxell ML, Bangs CD, Lawce HJ, et al: Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 126:709-716, 2006 (Pubitemid 44707621)
16. Starczynski J, Atkey N, Connelly Y, et al: HER2 gene amplification in breast cancer: A rogues' gallery of challenging diagnostic cases - UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 137:595-605, 2012
17. Chang MC, Malowany JI, Mazurkiewicz J, et al: "Genetic heterogeneity" in HER2/neu testing by fluorescence in situ hybridization: A study of 2,522 cases. Mod Pathol 25:683-688, 2012
18. Moeder CB, Giltnane JM, Harigopal M, et al: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: Tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418-5425, 2007 (Pubitemid 350232218)
19. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
20. Ohlschlegel C, Zahel K, Kradolfer D, et al: HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 64:1112-1116, 2011
21. Mrhalova M, Kodet R: A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: Comparison with HER-2/CEP17 ratio system. J Cancer Res Clin Oncol 133:321-329, 2007 (Pubitemid 46723500)
22. Perez EA, Press MF, Dueck AC, et al: Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138:99-108, 2013
23. Hanna WM, Rüschoff J, Bilous M, et al: HER2 in situ hybridization in breast cancer: Clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol [epub ahead of print on June 28, 2013]
24. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
25. Russell SD, Blackwell KL, Lawrence J, et al: Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421, 2010
26. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
27. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
28. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
29. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
30. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
31. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
32. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
33. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
34. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
35. Press MF, Finn RS, Cameron D, et al: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870, 2008
36. Gianni L, Llado A, Bianchi G, et al: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:1131-1137, 2010
37. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163, 2013
38. Paik S, Kim C, Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409-1411, 2008 (Pubitemid 351468442)
39. Middleton LP, Price KM, Puig P, et al: Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 guideline recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 133:775-780, 2009
40. Bartlett JM, Ibrahim M, Jasani B, et al: External quality assurance of HER2 FISH and ISH testing: Three years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106-111, 2009
41. Brunelli M, Manfrin E, Martignoni G, et al: HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy. Am J Clin Pathol 129:907-911, 2008
42. Reiner-Concin A, Regitnig P, Dinges HP, et al: Practice of HER-2 immunohistochemistry in breast carcinoma in Austria. Pathol Oncol Res 14:253-259, 2008
43. Khoury T, Sait S, Hwang H, et al: Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457-1467, 2009
44. Tong LC, Nelson N, Tsourigiannis J, et al: The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: A prospective study. Am J Surg Pathol 35:545-552, 2011
45. Hanley KZ, Birdsong GG, Cohen C, et al: Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer 117:279-288, 2009
46. Arber DA: Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10:183-186, 2002
47. Ibarra JA, Rogers LW: Fixation time does not affect expression of HER2/neu: A pilot study. Am J Clin Pathol 134:594-596, 2010
48. McCullough AE, Dell'Orto P, Reinholz MM, et al: Concordance of HER2 central assessment by two international central laboratories: A ring study within the framework of the adjuvant HER2-positive ALTTO trial (BIG2-06/N063D/EGF106708). Cancer Res 70, 2012 (suppl 2; abstr P3-10-36)
49. Perez EA, Dueck AC, McCullough AE, et al: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:159-162, 2012
50. Iorfida M, Dellapasqua S, Bagnardi V, et al: HER2-negative (1+) breast cancer with unfavorable prognostic features: To FISH or not to FISH? Ann Oncol 23:1371-1372, 2012
51. Hameed O, Adams AL, Baker AC, et al: Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol 130:425-427, 2008
52. Atkinson R, Mollerup J, Laenkholm AV, et al: Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: A study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med 135:1010-1016, 2011
53. Gilcrease MZ, Woodward WA, Nicolas MM, et al: Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33:759-767, 2009
54. Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599, 2012
55. Vincent-Salomon A, Pierga JY, Couturier J, et al: HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: A possible tool for anti-HER2 therapy management? Br J Cancer 96:654-659, 2007
56. Santiago MP, Vázquez-Boquete A, Fernández B, et al: Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis. Histol Histopathol 24:675-682, 2009
57. Wilking U, Karlsson E, Skoog L, et al: HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat 125:553-561, 2011
58. Bates M, Sperinde J, Köstler WJ, et al: Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 22:2014-2020, 2011
59. Lower EE, Glass E, Blau R, et al: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301-306, 2009
60. Guarneri V, Giovannelli S, Ficarra G, et al: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. Oncologist 13:838-844, 2008
61. Tapia C, Savic S, Wagner U, et al: HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31, 2007
62. Mittendorf EA, Wu Y, Scaltriti M, et al: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381-7388, 2009
63. Bartlett JM, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25:4423-4430, 2007 (Pubitemid 350013848)
64. Amir E, Clemons M, Purdie CA, et al: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multidisciplinary prospective studies. Cancer Treat Rev 38:708-714, 2012
65. Arnedos M, Nerurkar A, Osin P, et al: Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20:1948-1952, 2009
66. Lebeau A, Turzynski A, Braun S, et al: Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 28:3264-3270, 2010
67. D'Alfonso T, Liu YF, Monni S, et al: Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: Emerging questions and considerations addressed. Am J Surg Pathol 34:575-581, 2010
68. Apple SK, Lowe AC, Rao PN, et al: Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 22:1151-1159, 2009
69. Chivukula M, Bhargava R, Brufsky A, et al: Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 21:363-368, 2008 (Pubitemid 351441033)
70. Wood B, Junckerstorff R, Sterrett G, et al: A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 39:391-395, 2007 (Pubitemid 47221462)
71. Zustin J, Boddin K, Tsourlakis MC, et al: HER-2/neu analysis in breast cancer bone metastases. J Clin Pathol 62:542-546, 2009
72. Komatsu K, Nakanishi Y, Seki T, et al: Application of liquid-based preparation to fine needle aspiration cytology in breast cancer. Acta Cytol 52:591-596, 2008
73. Aitken SJ, Thomas JS, Langdon SP, et al: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21:1254-1261, 2010
74. Bilous M: Breast core needle biopsy: Issues and controversies. Mod Pathol 23:S36-S45, 2010 (suppl 2)
75. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907-922, 2010
76. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
77. Genentech: Highlights of prescribing information (Herceptin; trastuzumab) 2013. http://www.gene.com/download/pdf/herceptin-prescribing.pdf
78. Genentech: Highlights of prescribing information (Perjeta; pertuzumab) 2013. http://www.gene.com/download/pdf/perjeta-prescribing.pdf
79. Chibon F, de Mascarel I, Sierankowski G, et al: Prediction of HER2 gene status in Her2 2+ invasive breast cancer: A study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol 22:403-409, 2009
80. Mayr D, Heim S, Weyrauch K, et al: Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: Comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 55:716-723, 2009
81. Tse CH, Hwang HC, Goldstein LC, et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-HER2 targeted therapy. J Clin Oncol 29:4168-4174, 2011
82. Vanden Bempt I, Van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869-4874, 2008
83. Sińczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, et al: Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma: Comparison of in situ hybridization methods. Pol J Pathol 58:41-50, 2007 (Pubitemid 46770178)
84. Capizzi E, Gruppioni E, Grigioni AD, et al: Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: A comparative study with FISH, SISH, and immunohistochemistry. Diagn Mol Pathol 17:220-226, 2008
85. Powell WC, Roche PC, Tubbs RR: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: Comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 16:569, 2008
86. Nunes CB, Rocha RM, Reis-Filho JS, et al: Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 61:934-938, 2008
87. Gustavson MD, Bourke-Martin B, Reilly DM, et al: Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis. Appl Immunohistochem Mol Morphol 17:329-337, 2009
88. Egervari K, Szollosi Z, Nemes Z: Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203:169-177, 2007
89. Minot DM, Kipp BR, Root RM, et al: Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: Development of a standardized scoring method that correlates with FISH. Am J Clin Pathol 132:133-138, 2009
90. Hall BH, Ianosi-Irimie M, Javidian P, et al: Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls. BMC Med Imaging 8:11, 2008
91. Itoh H, Miyajima Y, Umemura S, et al: Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: Three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals. Cancer 114:134-140, 2008 (Pubitemid 351640793)
92. Roepman P, Horlings HM, Krijgsman O, et al: Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15:7003-7011, 2009
93. Bartlett JM, Campbell FM, Ibrahim M, et al: A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135:157-162, 2011
94. Pedersen M, Rasmussen BB: The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol 18:96-102, 2009
95. Francis GD, Jones MA, Beadle GF, et al: Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: Correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 18:88-95, 2009
96. Gong Y, Sweet W, Duh YJ, et al: Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: A study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol 132:228-236, 2009
97. Vocaturo A, Novelli F, Benevolo M, et al: Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: A sensitive and practical method in the trastuzumab era. Oncologist 11:878-886, 2006 (Pubitemid 44373760)
98. Hanna WM, Kwok K: Chromogenic in-situ hybridization: A viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 19:481-487, 2006
99. Rocha RM, Nunes CB, Sanches FS, et al: Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. Rev Assoc Med Bras 55:163-168, 2009
100. Cayre A, Mishellany F, Lagarde N, et al: Comparison of different commercial kits for HER2 testing in breast cancer: Looking for the accurate cutoff for amplification. Breast Cancer Res 9:R64, 2007
101. García-Caballero T, Grabau D, Green AR, et al: Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 56:472-480, 2010
102. Di Palma S, Collins N, Faulkes C, et al: Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol 60:1067-1068, 2007 (Pubitemid 47441949)
103. Sáez A, Andreu FJ, Seguí MA, et al: HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer - A study of two hundred cases. Breast 15:519-527, 2006 (Pubitemid 44149449)
104. Baehner FL, Achacoso N, Maddala T, et al: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300-4306, 2010
105. Shousha S, Peston D, Amo-Takyi B, et al: Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54:248-253, 2009
106. Faratian D, Graham A, Rae F, et al: Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54:428-432, 2009
107. Ni R, Mulligan AM, Have C, et al: PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol 15: 316-324, 2007 (Pubitemid 47329925)
108. Uzan C, Andre F, Scott V, et al: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer 117:32-39, 2009
109. Cuadros M, Talavera P, López FJ, et al: Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 77:38-45, 2010
110. Susini T, Bussani C, Marini G, et al: Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol 116:234-239, 2010
111. Huang W, Reinholz M, Weidler J, et al: Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol 134:303-311, 2010
112. Ashok M, Griffin P, Halpern M: Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer. Cancer Invest 28:735-742, 2010
113. Joensuu H, Sperinde J, Leinonen M, et al: Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 22:2007-2013, 2011
114. Monego G, Arena V, Maggiano N, et al: Borderline HER-2 breast cancer cases: Histochemical versus real-time PCR analysis and impact of different cut-off values. Scand J Clin Lab Invest 67:402-412, 2007 (Pubitemid 46897614)
115. Dobson L, Conway C, Hanley A, et al: Image analysis as an adjunct to manual HER-2 immunohistochemical review: A diagnostic tool to standardize interpretation. Histopathology 57:27-38, 2010
116. Masmoudi H, Hewitt SM, Petrick N, et al: Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer. IEEE Trans Med Imaging 28:916-925, 2009
117. Giltnane JM, Molinaro A, Cheng H, et al: Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med 132:1635-1647, 2008
118. Tubbs RR, Pettay JD, Swain E, et al: Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study. Appl Immunohistochem Mol Morphol 14:436-440, 2006 (Pubitemid 44813705)
119. Skaland I, Ovestad I, Janssen EA, et al: Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer. Appl Immunohistochem Mol Morphol 16:185-190, 2008
120. Skaland I, Ovestad I, Janssen EA, et al: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol 61:68-71, 2008 (Pubitemid 351158228)
121. Słodkowska J, Filas V, Buszkiewicz E, et al: Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem Cytobiol 48:19-25, 2010
122. Flanagan MB, Dabbs DJ, Brufsky AM, et al: Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 21:1255-1261, 2008
123. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
124. Dabbs DJ, Klein ME, Mohsin SK, et al: High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: An independent quality assurance study. J Clin Oncol 29:4279-4285, 2011
125. Nassar A, Cohen C, Siddiqui M: Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagn Cytopathol 37:865-870, 2009
126. Francz M, Egervari K, Kardos L, et al: Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: A validation study. J Clin Pathol 63:341-346, 2010
127. Bergqvist J, Ohd JF, Smeds J, et al: Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 18:845-850, 2007 (Pubitemid 47054080)
128. Barberis M, Pellegrini C, Cannone M, et al: Quantitative PCR and HER2 testing in breast cancer: A technical and cost-effectiveness analysis. Am J Clin Pathol 129:563-570, 2008 (Pubitemid 352029275)
129. Potemski P, Płuciennik E, Bednarek AK, et al: A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. Med Sci Monit 12:MT57-MT61, 2006
130. Papouchado BG, Myles J, Lloyd RV, et al: Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 34:767-776, 2010
131. Ricardo SA, Milanezi F, Carvalho ST, et al: HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 60:1001-1005, 2007 (Pubitemid 47441932)
132. Graham AD, Faratian D, Rae F, et al: Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: A prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52:847-855, 2008 (Pubitemid 351724917)
133. Mayr D, Heim S, Werhan C, et al: Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch 454:241-248, 2009
134. Wludarski SC, Bacchi CE: High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol 16:466-470, 2008
135. Ignatiadis M, Xenidis N, Perraki M, et al: Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194-5202, 2007 (Pubitemid 350232250)
136. Dowsett M, Hanna WM, Kockx M, et al: Standardization of HER2 testing: Results of an international proficiency-testing ring study. Mod Pathol 20:584-591, 2007 (Pubitemid 46632000)
137. Bartlett JM, Campbell FM, Ibrahim M, et al: A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: Intersite variation can be rigorously controlled using FISH. Histopathology 56:297-304, 2010
138. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
139. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
140. Reddy JC, Reimann JD, Anderson SM, et al: Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 7:153-157, 2006 (Pubitemid 44044012)
141. Sui W, Ou M, Chen J, et al: Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol 7:83, 2009
142. van de Vijver M, Bilous M, Hanna W, et al: Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: An international validation ring study. Breast Cancer Res 9:R68, 2007
143. Carbone A, Botti G, Gloghini A, et al: Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 10:527-536, 2008
144. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
145. Vani K, Sompuram SR, Fitzgibbons P, et al: National HER2 proficiency test results using standardized quantitative controls: Characterization of laboratory failures. Arch Pathol Lab Med 132:211-216, 2008 (Pubitemid 351213789)
146. Nofech-Mozes SJT, Hanna W, Khalifa M: Synoptic reporting on breast cancer biomarkers: A novel quality improvement module. Canadian J Pathol Winter 2011:11-15, 2011
147. American College of Physicians: Racial and Ethnic Disparities in Health Care 2010: Policy Paper. http://www.acponline.org/advocacy/current-policy- papers/assets/racial-disparities.pdf
148. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (vintage 2009 populations). http://seer.cancer.gov/csr/1975- 2009-pops09/
149. Mead H, Cartwright-Smith L, Jones K, et al: Racial and ethnic disparities in U.S. health care: A chartbook. http://www.commonwealthfund.org/usr-doc/Mead- racialethnicdisparities-chartbook-1111.pdf
150. Smedley BD, Stith AY, Neson AR: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC, National Academies Press, 2003
151. Lund MJ, Butler EN, Hair BY, et al: Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report. Cancer 116:2549-2559, 2010
152. Sparano JA, Wang M, Zhao F, et al: Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406-414, 2012
153. Ferrusi IL, Earle CC, Trudeau M, et al: Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care 19:838-844, 2013
154. Goddard KA, Weinmann S, Richert-Boe K, et al: HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics 15:1-10, 2012
155. Stark A, Kucera G, Lu M, et al: Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care 16:517-521, 2004 (Pubitemid 39625161)